Page 1

EX - 99.1 2 alks - ex991_6.htm EX - 99.1 Exhibit 99.1 Alkermes Contacts : For Investors : Sandy Coombs For Media : Katie Joyce Alkermes plc Reports Third Quarter 2021 Financial Results +1 781 609 6377 +1 781 249 8927 Third Quarter Revenues of $ 294.1 Million Reflect 11 % Growth Year - Over - Year- - Diluted GAAP Loss per Share of $ 0.18 and Diluted Non - GAAP Earnings per Share of $ 0.14 — DUBLIN , Oct. 27 , 2021 - _ Company Reiterates Financial Expectations for 2021 - Alkermes plc ( Nasdaq : ALKS ) today reported financial results for the third quarter of 2021 . " We have made significant strides across our commercial and development portfolios over the course of 2021. With the recent commercial launch of LYBALVI® , we have expanded our psychiatry franchise and added an important new growth opportunity that leverages our experience and capabilities in the antipsychotic market . Within our development pipeline , we initiated clinical studies designed to support potential registration of nemvaleukin in mucosal melanoma and platinum- resistant ovarian cancer . We also initiated a phase 1 study of ALKS 1140 and advanced our preclinical orexin 2 receptor agonist program . Each of these important achievements demonstrates the continued execution of our strategy to advance differentiated medicines in neuroscience and oncology , " said Richard Pops , Chief Executive Officer of Alkermes . " As we look ahead , we believe we are well - positioned to deliver long - term growth and value creation , driven by our diversified commercial business , our advancing development pipeline and our focus on profitability . ” Quarter Ended Sept. 30 , 2021 Financial Results Revenues • • Total revenues for the quarter were $ 294.1 million . This compared to $ 265.0 million for the same period in the prior year . Net sales of proprietary products for the quarter were $ 157.7 million , compared to $ 142.7 million for the same period in the prior year . о ○ Net sales of VIVITROL® were $ 88.8 million , compared to $ 80.3 million for the same period in the prior year , representing an increase of approximately 11 % . Net sales of ARISTADA®1 were $ 68.9 million , compared to $ 62.4 million for the same period in the prior year , representing an increase of approximately 10 % . Manufacturing and royalty revenues for the quarter were $ 136.3 million , compared to $ 120.4 million for the same period in the prior year . ○ о Costs and Expenses • Manufacturing and royalty revenues from INVEGA SUSTENNA® / XEPLION® , INVEGA TRINZAⓇ / TREVICTA® , and RISPERDAL CONSTA® were $ 90.3 million , compared to $ 87.9 million for the same period in the prior year . Manufacturing and royalty revenues from VUMERITY® were $ 26.7 million , compared to $ 2.7 million for the same period in the prior year . Total operating expenses for the quarter were $ 313.8 million , compared to $ 275.7 million for the same period in the prior year . о Cost of Goods Manufactured and Sold were $ 49.6 million , compared to $ 43.1 million for the same period in the prior year . о Research and Development ( R & D ) expenses were $ 118.4 million , compared to $ 95.0 million for the same period in the prior year . R & D expenses for the third quarter included